Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
A Carobbio, A Ferrari, A Masciulli, A Ghirardi… - Blood …, 2019 - ashpublications.org
In the last years, a growing amount of evidence has been produced regarding the role of
leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms …
leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms …
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
T Rungjirajittranon, W Owattanapanich, P Ungprasert… - BMC cancer, 2019 - Springer
Abstract Background Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms
(MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most …
(MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
F Passamonti, M Griesshammer, F Palandri… - The Lancet …, 2017 - thelancet.com
Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK) 1 and JAK2
inhibitor, was superior to best available therapy at controlling haematocrit and improving …
inhibitor, was superior to best available therapy at controlling haematocrit and improving …
[HTML][HTML] Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review
SB Todor, C Ichim, A Boicean, RG Mihaila - Current Issues in Molecular …, 2024 - mdpi.com
Myeloproliferative neoplasms (MPNs), encompassing disorders like polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by …
essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by …
Thromboembolic events in polycythemia vera
M Griesshammer, JJ Kiladjian, C Besses - Annals of hematology, 2019 - Springer
Thromboembolic events and cardiovascular disease are the most prevalent complications in
patients with polycythemia vera (PV) compared with other myeloproliferative disorders and …
patients with polycythemia vera (PV) compared with other myeloproliferative disorders and …
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
CN Harrison, S Koschmieder, L Foltz, P Guglielmelli… - Annals of …, 2017 - Springer
Abstract Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced …
are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced …
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline
1Centre for Medical Education, Queen's University, Belfast, 2MRC Molecular Haematology
Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine …
Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine …
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
TA Knudsen, V Skov, K Stevenson, L Werner… - Blood …, 2022 - ashpublications.org
Although somatic mutations influence the pathogenesis, phenotype, and outcome of
myeloproliferative neoplasms (MPNs), little is known about their impact on molecular …
myeloproliferative neoplasms (MPNs), little is known about their impact on molecular …
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V De Stefano, AM Vannucchi, M Ruggeri… - Blood cancer …, 2016 - nature.com
We retrospectively studied 181 patients with polycythaemia vera (n= 67), essential
thrombocythaemia (n= 67) or primary myelofibrosis (n= 47), who presented a first episode of …
thrombocythaemia (n= 67) or primary myelofibrosis (n= 47), who presented a first episode of …